JP2017515857A5 - - Google Patents

Info

Publication number

JP2017515857A5

JP2017515857A5 JP2016567656A JP2016567656A JP2017515857A5 JP 2017515857 A5 JP2017515857 A5 JP 2017515857A5 JP 2016567656 A JP2016567656 A JP 2016567656A JP 2016567656 A JP2016567656 A JP 2016567656A JP 2017515857 A5 JP2017515857 A5 JP 2017515857A5

Authority

JP

Japan

Prior art keywords

optionally substituted

composition

compound according

alkyl

ring

Prior art date

2015-05-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 63
• 125000000217 alkyl group Chemical group 0.000 claims description 33
• 229910052736 halogen Inorganic materials 0.000 claims description 26
• 239000000203 mixture Substances 0.000 claims description 24
• 229910052739 hydrogen Inorganic materials 0.000 claims description 23
• 239000001257 hydrogen Substances 0.000 claims description 23
• 150000002367 halogens Chemical class 0.000 claims description 22
• 206010028980 Neoplasm Diseases 0.000 claims description 17
• 201000011510 cancer Diseases 0.000 claims description 17
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
• 125000005842 heteroatom Chemical group 0.000 claims description 12
• 229910052757 nitrogen Inorganic materials 0.000 claims description 12
• 229910052760 oxygen Inorganic materials 0.000 claims description 12
• 239000001301 oxygen Chemical group 0.000 claims description 12
• 229910052717 sulfur Chemical group 0.000 claims description 12
• 239000011593 sulfur Chemical group 0.000 claims description 12
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
• 125000001072 heteroaryl group Chemical group 0.000 claims description 8
• 125000000623 heterocyclic group Chemical group 0.000 claims description 8
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
• 125000004043 oxo group Chemical group O=* 0.000 claims description 8
• 150000003839 salts Chemical class 0.000 claims description 8
• 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims description 7
• 125000002541 furyl group Chemical group 0.000 claims description 6
• 150000002431 hydrogen Chemical group 0.000 claims description 6
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
• 102000011727 Caspases Human genes 0.000 claims description 5
• 108010076667 Caspases Proteins 0.000 claims description 5
• 230000000694 effects Effects 0.000 claims description 5
• 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 4
• 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 4
• 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 claims description 4
• 125000001931 aliphatic group Chemical group 0.000 claims description 4
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
• 201000010099 disease Diseases 0.000 claims description 4
• 208000035475 disorder Diseases 0.000 claims description 4
• 125000005843 halogen group Chemical group 0.000 claims description 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
• 125000004076 pyridyl group Chemical group 0.000 claims description 4
• 238000003556 assay Methods 0.000 claims description 3
• 238000003776 cleavage reaction Methods 0.000 claims description 3
• 230000002401 inhibitory effect Effects 0.000 claims description 3
• 230000007017 scission Effects 0.000 claims description 3
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
• 230000003213 activating effect Effects 0.000 claims description 2
• 239000002246 antineoplastic agent Substances 0.000 claims description 2
• 230000006907 apoptotic process Effects 0.000 claims description 2
• 230000004663 cell proliferation Effects 0.000 claims description 2
• 229940127089 cytotoxic agent Drugs 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 230000001939 inductive effect Effects 0.000 claims description 2
• 230000005764 inhibitory process Effects 0.000 claims description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims description 2
• 125000001544 thienyl group Chemical group 0.000 claims description 2
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• 238000000034 method Methods 0.000 description 17
• 230000003834 intracellular effect Effects 0.000 description 1
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1